A empresa farmacêutica Meda Pharma anunciou um acordo definitivo para a aquisição da empresa Rottapharm. Leia a notícia divulgada pelo portal FirstWord.

Meda to buy Rottapharm for $3.1 billion, boosting emerging market, consumer health presence. Meda announced Thursday a definitive agreement to acquire specialty pharmaceutical company Rottapharm for 21.2 Swedish kroner ($3.1 billion), boosting its portfolio of prescription drugs and consumer healthcare products, whilst expanding in emerging markets. Meda CEO Jörg-Thomas Dierks remarked that Rottapharm has "highly differentiated brands and a leading position" within consumer health.

Dierks noted that "the combined business will have an improved [prescription drug/consumer health] balance and increased investment opportunities," He added that the deal "is in-line with our strategic priorities to execute value-accretive M&A, invest in consumer healthcare and emerging markets."

Meda said that the transaction includes 15.3 billion kroner ($2.2 billion) in cash, 30 million Meda shares corresponding to a value of 3.3 billion kroner ($479 million) and a non-contingent deferred payment in January 2017 of 2.6 billion kroner ($377 million). Following completion of the acquisition, which is expected in the fourth quarter, the founders of Rottapharm will own 9 percent of Meda.

http://www.firstwordpharma.com/node/1227640?tsid=28#axzz392KZqRDM